A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the tolerability and safety of Daratumumab in
Japanese participants with relapsed (the return of a medical problem) or refractory (not
responding to treatment) multiple myeloma (cancer of plasma cells in bone marrow,
characterized by the presence of abnormal proteins in the blood).